{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:37Z","timestamp":1787786077402,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R388-A23078"],"award-info":[{"award-number":["R388-A23078"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R231-A13845"],"award-info":[{"award-number":["R231-A13845"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R257-A14700"],"award-info":[{"award-number":["R257-A14700"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","award":["FID1839672"],"award-info":[{"award-number":["FID1839672"]}],"id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Krista and Viggo Foundation","award":["6030\/67"],"award-info":[{"award-number":["6030\/67"]}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["9068-00046B"],"award-info":[{"award-number":["9068-00046B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF17OC0025052"],"award-info":[{"award-number":["NNF17OC0025052"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22OC0074415"],"award-info":[{"award-number":["NNF22OC0074415"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R481-2024-1234"],"award-info":[{"award-number":["R481-2024-1234"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy has potential benefit in patients with localized colon cancer with proficient mismatch repair (pMMR). However, patient selection is a major challenge. We explored whether pre-operative circulating tumor DNA (pre-op ctDNA) would be helpful in selecting high-risk patients for neoadjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pre-op ctDNA levels were determined using blood samples from patients undergoing potentially curative surgery for localized pMMR colon cancer. Associations between pre-op ctDNA and pathological stage, positive (R1) resection margins and disease recurrence were investigated. Predictive models for these outcomes using routinely available clinical factors with and without pre-op ctDNA were developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 979 patients were included. Pre-op ctDNA was significantly associated with pathological stage, although no difference between patients with stage II and III disease was noted (positive patients: stage I 28% versus stage II 67% versus stage III 75%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Pre-op ctDNA was also associated with R1 resection (positive patients: R0 59% versus R1 82%,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.017). Patients with positive pre-op ctDNA had increased 3-year cumulative incidence of recurrence after surgery (23% [95% CI 18\u201328] versus 5.3% [95% CI 2.6\u20139.4];\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001), most of which occurred within 12 months of surgery. Although the addition of ctDNA to clinical predictive models did not improve prediction of pathological stage or R1 status, it had some value in identifying early recurrence after surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-op ctDNA is associated with pathological stage, R1 resection, and recurrence after surgery in patients with localized pMMR colon cancer. However, its value in improving the selection of high-risk patients for neoadjuvant chemotherapy requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19539-8","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:05:57Z","timestamp":1775243157000},"page":"6530-6539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-4648","authenticated-orcid":false,"given":"Henry G.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenna V.","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Lindbjerg","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the IMPROVE Study Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bondeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Vadgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Thorlacius-Ussing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe Schou","family":"L\u00f8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Kildsig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Gogenur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nis Hallundb\u00e6k","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kolbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Hjerrild","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re Andersson","family":"Gotschalck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"10","key":"19539_CR1","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argiles","year":"2020","unstructured":"Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291\u2013305.","journal-title":"Ann Oncol."},{"issue":"19","key":"19539_CR2","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109\u201316.","journal-title":"J Clin Oncol."},{"issue":"6","key":"19539_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/0284186X.2023.2218555","volume":"62","author":"HG Smith","year":"2023","unstructured":"Smith HG, Skovgaards DM, Bui NH, Chiranth D, Qvortrup C, Schlesinger NH. Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer. Acta Oncol. 2023;62(6):594\u2013600.","journal-title":"Acta Oncol."},{"issue":"1","key":"19539_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","volume":"10","author":"J Nors","year":"2024","unstructured":"Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: A Nationwide Danish cohort study. JAMA Oncol. 2024;10(1):54\u201362.","journal-title":"JAMA Oncol."},{"issue":"1","key":"19539_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med."},{"key":"19539_CR6","doi-asserted-by":"crossref","unstructured":"Medical Research Council Oesophageal Cancer Working G. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359 (9319):1727-33","DOI":"10.1016\/S0140-6736(02)08651-8"},{"issue":"4","key":"19539_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","volume":"271","author":"M Karoui","year":"2020","unstructured":"Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020;271(4):637\u201345.","journal-title":"Ann Surg."},{"issue":"17","key":"19539_CR8","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3503","volume":"41","author":"LH Jensen","year":"2023","unstructured":"Jensen LH, Kjaer ML, Larsen FO, Hollander NH, Rahr HB, Pfeffer F, et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol. 2023;41(17):3503.","journal-title":"J Clin Oncol."},{"issue":"8","key":"19539_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541\u201352.","journal-title":"J Clin Oncol."},{"issue":"4","key":"19539_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376.","journal-title":"Nat Med."},{"issue":"21","key":"19539_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358.","journal-title":"N Engl J Med."},{"key":"19539_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006611","author":"I Gogenur","year":"2024","unstructured":"Gogenur I, Justesen TF, Tarpgaard LS, Bulut M, Hansen TF, Jensen LH, et al. Neoadjuvant pembrolizumab in stage I-III deficient mismatch repair colon cancer: a clinical trial. Ann Surg Epub. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006611.","journal-title":"Ann Surg. Epub"},{"issue":"1","key":"19539_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00384-017-2932-3","volume":"33","author":"ML Malmstrom","year":"2018","unstructured":"Malmstrom ML, Brisling S, Klausen TW, Saftoiu A, Perner T, Vilmann P, Gogenur I. Staging with computed tomography of patients with colon cancer. Int J Colorectal Dis. 2018;33(1):9\u201317.","journal-title":"Int J Colorectal Dis."},{"issue":"2","key":"19539_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","volume":"35","author":"TV Henriksen","year":"2024","unstructured":"Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort. Ann Oncol. 2024;35(2):229\u201339.","journal-title":"Ann Oncol."},{"issue":"3","key":"19539_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28(3):507\u201317.","journal-title":"Clin Cancer Res."},{"issue":"346","key":"19539_CR16","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.","journal-title":"Sci Transl Med."},{"issue":"2","key":"19539_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","volume":"35","author":"TV Henriksen","year":"2024","unstructured":"Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann Oncol. 2024;35(2):229\u201339.","journal-title":"Ann Oncol."},{"issue":"8","key":"19539_CR18","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3390\/ijms25084252","volume":"25","author":"A Frydendahl","year":"2024","unstructured":"Frydendahl A, Rasmussen MH, Jensen SO, Henriksen TV, Demuth C, Diekema M, et al. Error-corrected deep targeted sequencing of circulating cell-free DNA from colorectal cancer patients for sensitive detection of circulating tumor DNA. Int J Mol Sci. 2024;25(8):4252.","journal-title":"Int J Mol Sci."},{"issue":"10","key":"19539_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41416-024-02867-5","volume":"131","author":"N Ogaard","year":"2024","unstructured":"Ogaard N, Jensen SO, Orntoft MW, Demuth C, Rasmussen MH, Henriksen TV, et al. Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer. Br J Cancer. 2024;131(10):1707\u201315.","journal-title":"Br J Cancer."},{"issue":"5","key":"19539_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdx030","volume":"28","author":"E Auclin","year":"2017","unstructured":"Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, et al. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol. 2017;28(5):958\u201368.","journal-title":"Ann Oncol."},{"issue":"11","key":"19539_CR21","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3390\/cancers12113308","volume":"12","author":"E Osterman","year":"2020","unstructured":"Osterman E, Hammarstrom K, Imam I, Osterlund E, Sjoblom T, Glimelius B. Recurrence risk after radical colorectal cancer surgery-less than before, but how high is it? Cancers (Basel). 2020;12(11):3308.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"19539_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1200\/JCO.2015.65.3048","volume":"34","author":"LA Pahlman","year":"2016","unstructured":"Pahlman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke P, Glimelius B. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol. 2016;34(12):1297\u20139.","journal-title":"J Clin Oncol."},{"issue":"3","key":"19539_CR23","doi-asserted-by":"publisher","first-page":"zrae38","DOI":"10.1093\/bjsopen\/zrae038","volume":"8","author":"HG Smith","year":"2024","unstructured":"Smith HG, Nilsson PJ, Shogan BD, Harji D, Gambacorta MA, Romano A, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3):zrae38.","journal-title":"BJS Open."},{"issue":"2","key":"19539_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/codi.15971","volume":"24","author":"HG Smith","year":"2022","unstructured":"Smith HG, Chiranth D, Mortensen CE, Schlesinger NH. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: A retrospective study of a national cancer registry. Colorectal Dis. 2022;24(2):197\u2013209.","journal-title":"Colorectal Dis."},{"issue":"7","key":"19539_CR25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/codi.16121","volume":"24","author":"HG Smith","year":"2022","unstructured":"Smith HG, Skovgaards DM, Chiranth D, Schlesinger NH. The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer - A retrospective cohort study. Colorectal Dis. 2022;24(7):828\u201337.","journal-title":"Colorectal Dis."},{"issue":"11","key":"19539_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/bjs.6739","volume":"96","author":"TE Bernstein","year":"2009","unstructured":"Bernstein TE, Endreseth BH, Romundstad P, Wibe A. Norwegian colorectal cancer G. circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg. 2009;96(11):1348\u201357.","journal-title":"Br J Surg."},{"issue":"4","key":"19539_CR27","doi-asserted-by":"publisher","first-page":"iv263","DOI":"10.1093\/annonc\/mdy161","volume":"29","author":"R Glynne-Jones","year":"2018","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):iv263.","journal-title":"Ann Oncol."},{"issue":"4","key":"19539_CR28","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00330-022-09222-3","volume":"33","author":"N Seo","year":"2023","unstructured":"Seo N, Lim JS, Chung T, Lee JM, Min BS, Kim MJ. Preoperative computed tomography assessment of circumferential resection margin in retroperitonealized colon cancer predicts disease-free survival. Eur Radiol. 2023;33(4):2757\u201367.","journal-title":"Eur Radiol."},{"key":"19539_CR29","doi-asserted-by":"publisher","first-page":"109127","DOI":"10.1016\/j.surg.2024.109127","volume":"180","author":"K Takura","year":"2025","unstructured":"Takura K, Miyake M, Kikkawa N, Kato T, Nagata H, Takamizawa Y, et al. Prognostic significance of the retroperitoneal surgical resection margin on computed tomography colonography in retroperitonealized colon cancer. Surgery. 2025;180:109127.","journal-title":"Surgery."},{"issue":"9","key":"19539_CR30","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3390\/cancers14092218","volume":"14","author":"SJ Schraa","year":"2022","unstructured":"Schraa SJ, van Rooijen KL, Koopman M, Vink GR, Fijneman RJA. Cell-free circulating (Tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review. Cancers (Basel). 2022;14(9):2218.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"19539_CR31","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/annonc\/mdr404","volume":"23","author":"JW Huh","year":"2012","unstructured":"Huh JW, Jeong YY, Kim HR, Kim YJ. Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer. Ann Oncol. 2012;23(5):1198\u2013206.","journal-title":"Ann Oncol."},{"issue":"7","key":"19539_CR32","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/sj.bjc.6603646","volume":"96","author":"NJ Smith","year":"2007","unstructured":"Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer. 2007;96(7):1030\u20136.","journal-title":"Br J Cancer."},{"issue":"9","key":"19539_CR33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","volume":"31","author":"TV Henriksen","year":"2025","unstructured":"Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH, et al. Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer. Clin Cancer Res. 2025;31(9):1676\u201385.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19539-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:29Z","timestamp":1780761149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19539-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19539"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19539-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The Danish National Committee on Health Research Ethics and Committees on Biomedical Research Ethics in the Central Region of Denmark approved the study (1-16-02-453-14, 1-10-72-3-18). The study was performed in accordance with the Declaration of Helsinki, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}